TBPH — Theravance Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1583107 ·
Last close
$16.93
Market Cap
$877.45M
52W High
$17.74
52W Low
$15.52
ADV30
738,371
Next earnings
2026-05-07
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 17,699,000 | — | -5,850,000 | -4,933,000 | 472,313,000 | 288,101,000 | 181,719,000 |
| Dec 2025 | 45,891,000 | — | 20,011,000 | 61,024,000 | 485,570,000 | 167,806,000 | 188,847,000 |
| Sep 2025 | 19,990,000 | — | -6,455,000 | 3,615,000 | 415,460,000 | 174,773,000 | 182,779,000 |
| Jun 2025 | 26,195,000 | — | -2,725,000 | 54,835,000 | 426,035,000 | 281,927,000 | 201,187,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$238,541,000
Investing CF
$-105,284,000
Financing CF
$-3,248,000
CapEx
$-213,000
Dividends Paid
—
Buybacks
$-4,034,000
EPS Diluted TTM
$2.03
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-859,627,000
Inventory
—
Receivables
$95,539,000
ST Investments
$147,551,000
EBIT TTM
$131,708,000
Pretax Income TTM
$129,247,000
Interest Exp TTM
$2,461,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$109,775,000
EBITDA
$6,576,000
Free Cash Flow
$22,506,500
Enterprise Value
$521,208,032
Total Cash
$394,665,984
Total Debt
$40,504,000
Shares Out
51,828,254
Trailing EPS
$2.23
Book Value
$5.64
ROE
50.2%
ROA
0.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 107,464,000 | -3,602,000 | 105,895,000 | 485,570,000 | 188,847,000 | — | 238,541,000 |
| Dec 2024 | 64,381,000 | -42,436,000 | -56,418,000 | 354,161,000 | 178,616,000 | — | -11,535,000 |
| Dec 2023 | 57,424,000 | -53,292,000 | -55,193,000 | 381,999,000 | 169,004,000 | — | -26,997,000 |
| Dec 2022 | 51,346,000 | -79,119,000 | 872,132,000 | 607,400,000 | 165,600,000 | — | -186,991,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.80
Max Pain — expiry 2026-09-18
max pain strike: $15.00 · spot: $16.93 · call oi: 57 · put oi: 1,369
Expected Move to 2026-09-18:
±$0.75
(4.43%) —
implied range
$16.18 –
$17.68
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $898.31M | $6.09 | — |
| FBRX | Forte Biosciences, Inc. | $899.43M | $43.92 | — |
| IVEVF | Inventiva S.A. | $848.03M | $3.59 | — |
| ANRO | Alto Neuroscience, Inc. | $929.29M | $26.48 | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $825.42M | $18.72 | — |
News headlines (Yahoo Finance, 1h cache)
Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run
2026-07-01 10:10 · Yahoo
Theravance Stock Down 3% After Zymeworks Announces Buyout
2026-06-30 12:54 · Yahoo
Zymeworks agrees to buy Theravance Biopharma for $929m
2026-06-30 08:26 · Yahoo
Sector Update: Healthcare Stocks Higher Late Afternoon
2026-06-29 19:59 · Yahoo
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders
2026-06-29 12:44 · Yahoo
Zymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.
2026-06-29 12:39 · Yahoo
Zymeworks to Acquire Theravance Biopharma in $929 Million Deal
2026-06-29 10:19 · Yahoo
Zymeworks to Acquire Theravance Biopharma, Inc.
2026-06-29 10:00 · Yahoo
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
2026-06-29 10:00 · Yahoo
Theravance, after clinical setbacks, agrees to $929M buyout
2026-06-29 08:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.